High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival

Breast Cancer Research and Treatment

Volumn 80, Issue 1, 2003, Pages 15-21

  Johansen, Julia S ^a   Christensen, Ib J ^b   Riisbro, Rikke ^b   Greenall, Michael ^c   Han, Chen ^d   Price, Paul A ^e   Smith, Kenneth ^d   Brünner, Nils ^b,f   Harris, Adrian L ^d  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Human cartilage gp 39; Primary breast cancer; Prognostic factors and survival; YKL 40

Indexed keywords

ESTROGEN RECEPTOR; GLYCOPROTEIN GP 39; GROWTH FACTOR; UNCLASSIFIED DRUG; YKL 40;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CELL MIGRATION; COLORECTAL CANCER; CONNECTIVE TISSUE CELL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENSTRUATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; AUTOANTIGENS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLYCOPROTEINS; HUMANS; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037485763     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024431000710     Document Type: Article

References (28)

1. Hakala BE, White C, Recklies AD: Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 268: 25803-25810, 1993
2. Morrison BW, Leder P: neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 9: 3417-3426, 1994
3. Shackelton LM, Mann DM, Millis AJ: Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 270: 13076-13083, 1995
4. Johansen JS, Williamson MK, Rice JS, Price PA: Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 7: 501-512, 1992
5. Rehli M, Krause SW, Andreesen R: Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43: 221-225, 1997
6. Tanwar MK, Gilbert MR, Holland EC: Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62: 4364-4368, 2002
7. Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, Hrebicek M, Aerts JMFG: Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 251: 504-509, 1998
8. Recklies AD, White C, Ling H: The chitinase 3-like protein human cartilage 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 365: 119-126, 2002
9. De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P: YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 285: 926-931, 2001
10. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ: Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250: 168-173, 1999
11. Boot RG, van Achterberg TAE, van Aken BE, Renkema GH, Jacobs MJHM, Aerts JMFG, de Vries CJM: Strong induction of members of the chitinase family of proteins in atherosclerosis. Chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscl Throm Vas 19: 687-694, 1999
12. Baeten D, Boots AMH, Steenbakkers PGA, Elewaut D, Bos E, Verheijden GFM, Verbruggen G, Miltenburg AMM, Rijnders AWM, Veys EM, De Keyser F: Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium. Correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 43: 1233-1243, 2000
13. Johansen JS, Baslund B, Garbarsch C, Hansen M, Stoltenberg M, Lorenzen I, Price PA: YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum 42: 2624-2630, 1999
14. Volck B, Johansen JS, Stoltenberg M, Garbarsch C, Price PA, Østergaard M, Ostergaard K, Løvgreen-Nielsen P, Sonne-Holm S, Lorenzen I: Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 9: 203-214, 2001
15. Volck B, Price PA, Johansen JS, Sørensen O, Benfield TL, Nielsen HJ, Calafat J, Borregaard N: YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110: 351-360, 1998
16. Johansen JS, Stoltenberg M, Hansel M, Florescu A, Hørslev-Petersen K, Lorenzen I, Price PA: Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology 38: 618-626, 1999
17. Johansen JS, Christoffersen P, Møller S, Price PA, Henriksen JH, Garbarsch C, Bendtsen F: Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 32: 911-920, 2000
18. Nordenbaek C, Johansen JS, Junker P, Borregaard N, Sørensen O, Price PA: YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis 180: 1722-1726, 1999
19. Harvey S, Weisman M, O'Dell J, Scott T, Krusemeier M, Visor J, Swindlehurst C: Chondrex: new marker of joint disease. Clin Chem 44: 509-516, 1998
20. Tran A, Benzaken S, Saint-Paul M-C, Guzman-Granier E, Hastier P, Pradier C, Barjoan EM, Demuth N, Longo F, Rampal P: Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 12: 989-993, 2000
21. Johansen JS, Cintin C, Jørgensen M, Kamby C, Price PA: Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer 31A: 1437-1442, 1995
22. Jensen BV, Johansen JS, Price PA: High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res (submitted)
23. Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ: Serum YKL-40 and colorectal cancer. Brit J Cancer 79: 1494-1499, 1999
24. Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ: High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 95: 267-274, 2002
25. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Høyer-Hansen G, Smith K, Brünner N, Harris AL: Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 8: 1132-1141, 2002
26. Royston P: Constructing time-specific reference ranges. Stat Med 10: 675-690, 1991
27. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA: Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Brit J Rheumatol 35: 553-559, 1996
28. Reitmeir P, Wassmer G: Resampling-based methods for the analysis of multiple endpoints in clinical trials. Stat Med 18: 3453-3462, 1999